- Home
- BRT vs TNXP Comparison
BRT vs TNXP Comparison
Compare BRT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- TNXP
- Stock Information
- Founded
- BRT 1972
- TNXP 2007
- Country
- BRT United States
- TNXP United States
- Employees
- BRT N/A
- TNXP N/A
- Industry
- BRT Real Estate Investment Trusts
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- TNXP Health Care
- Exchange
- BRT Nasdaq
- TNXP Nasdaq
- Market Cap
- BRT 288.5M
- TNXP 335.6M
- IPO Year
- BRT N/A
- TNXP N/A
- Fundamental
- Price
- BRT $16.47
- TNXP $28.37
- Analyst Decision
- BRT Strong Buy
- TNXP Buy
- Analyst Count
- BRT 1
- TNXP 1
- Target Price
- BRT $21.00
- TNXP $70.00
- AVG Volume (30 Days)
- BRT 25.0K
- TNXP 1.2M
- Earning Date
- BRT 11-06-2025
- TNXP 11-11-2025
- Dividend Yield
- BRT 6.06%
- TNXP N/A
- EPS Growth
- BRT N/A
- TNXP N/A
- EPS
- BRT N/A
- TNXP N/A
- Revenue
- BRT $98,407,000.00
- TNXP $9,831,000.00
- Revenue This Year
- BRT N/A
- TNXP $14.79
- Revenue Next Year
- BRT $4.51
- TNXP $933.49
- P/E Ratio
- BRT N/A
- TNXP N/A
- Revenue Growth
- BRT 2.46
- TNXP N/A
- 52 Week Low
- BRT $14.17
- TNXP $6.76
- 52 Week High
- BRT $20.22
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- BRT 62.89
- TNXP 41.43
- Support Level
- BRT $16.01
- TNXP $26.89
- Resistance Level
- BRT $16.69
- TNXP $29.19
- Average True Range (ATR)
- BRT 0.42
- TNXP 2.18
- MACD
- BRT 0.05
- TNXP 0.39
- Stochastic Oscillator
- BRT 82.95
- TNXP 56.73
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.